Breast Patents (Class 514/19.4)
-
Patent number: 8900600Abstract: The present invention discloses peptides such as an isolated peptide consisting of an immunogenic HLA-A*2402-restricted epitope. For example, the isolated peptide may be selected from the group consisting of KYGVLLKTL (SEQ ID NO:11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16).Type: GrantFiled: April 2, 2009Date of Patent: December 2, 2014Assignee: VAXON BiotechInventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
-
Publication number: 20140349920Abstract: N-acylpeptide derivatives are described. Compositions comprising N-acylpeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with tumors or cancers, immune, nervous, vascular, musculoskeletal, cutaneous system, or other tissues or systems in a subject.Type: ApplicationFiled: January 3, 2013Publication date: November 27, 2014Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Patent number: 8895500Abstract: The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved binding affinity to the tumor necrosis factor.Type: GrantFiled: September 7, 2011Date of Patent: November 25, 2014Assignee: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Publication number: 20140342994Abstract: Provided is a fusion protein comprising circularly permuted form of TRAIL, and the fusion protein contains circularly permuted form of TRAIL and oligopeptides located at the N-terminus and/or C-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines. The components of the circularly permuted form of TRAIL from N-terminus to C-terminus are: (a) amino acids 135-281 of TRAIL, (b) a linker, and (c) amino acids 121-135 of TRAIL or amino acids 114-135 of TRAIL or amino acids 95-135 of TRAIL or any fragments of amino acids 95-135 of TRAIL containing amino acids 121-135 of TRAIL. Also provided is a method for treating cancer by using the fusion protein.Type: ApplicationFiled: September 16, 2011Publication date: November 20, 2014Applicant: Beijing Sunbio Biotech Co., Ltd.Inventors: Shifang Yang, Junsheng Cui, Bing Zhu, Peng Wei
-
Publication number: 20140342993Abstract: The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population.Type: ApplicationFiled: April 22, 2014Publication date: November 20, 2014Applicant: PURDUE RESEARCH FOUNDATIONInventors: Alyssa PANITCH, Brandon SEAL, Brian WARD
-
Patent number: 8889616Abstract: Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.Type: GrantFiled: February 23, 2012Date of Patent: November 18, 2014Assignee: Oncothyreon Inc.Inventors: Scott Peterson, Linda Pestano, Jeffrey Millard, Diana F. Hausman, Sandy Koppenol, Robert Kirkman
-
Publication number: 20140336108Abstract: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.Type: ApplicationFiled: July 28, 2014Publication date: November 13, 2014Inventors: Xialing Guo, Zhen Zhu
-
Patent number: 8883966Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.Type: GrantFiled: October 15, 2009Date of Patent: November 11, 2014Assignee: OncoTherapy Science, Inc.Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
-
Patent number: 8883120Abstract: HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO:1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2.Type: GrantFiled: June 27, 2013Date of Patent: November 11, 2014Assignee: Affibody ABInventors: Lars Abrahmsén, Nina Herne, Joachim Feldwisch, Christofer Lendel, Vladimir Tolmachev
-
Publication number: 20140329760Abstract: Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.Type: ApplicationFiled: October 23, 2013Publication date: November 6, 2014Applicants: Mayo Foundation for Medical Education and Research, Trustees of Dartmouth CollegeInventors: Debabrata Mukhopadhyay, Priyabrata Mukherjee, Mark Spaller
-
Publication number: 20140328858Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.Type: ApplicationFiled: May 2, 2014Publication date: November 6, 2014Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
-
Patent number: 8877715Abstract: There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors.Type: GrantFiled: August 18, 2011Date of Patent: November 4, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
-
Publication number: 20140322332Abstract: The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.Type: ApplicationFiled: April 1, 2014Publication date: October 30, 2014Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Donald W. KUFE, Surender KHARBANDA
-
Publication number: 20140323390Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.Type: ApplicationFiled: July 9, 2014Publication date: October 30, 2014Applicant: IRM LLCInventors: Tom Yao-Hsiang WU, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
-
Publication number: 20140322132Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 8865642Abstract: The invention provides compositions comprising soluble extracts or isolated polypeptides from the edible roots of the plant Colocasia, such as Colocasia esculenta, commonly known as Taro, and from Xanthosoma, such as Xanthosoma sagittifolium, commonly known as Malanga Blanca or Yautia. The compositions exhibit inhibitory effects on metastasis of cancer cells in particular breast and prostate cancer cells and have therapeutic pharmacological activity, Pharmaceutical compositions for the treatment of cancer by inhibiting metastasis which comprises an effective amount of the described extract or isolated polypeptide thereof and optionally a pharmaceutical acceptable carrier are described.Type: GrantFiled: December 17, 2010Date of Patent: October 21, 2014Assignee: University of Maryland, BaltimoreInventors: Amy Fulton, Namita Kundu
-
Publication number: 20140309174Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.Type: ApplicationFiled: November 12, 2013Publication date: October 16, 2014Applicant: Eisai Co., LtdInventors: James J. Kowalczyk, Galina Kuznetsov, Shawn Schiller, Boris M. Seletsky, Mark Spyvee, Hu Yang
-
Publication number: 20140303080Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Publication number: 20140294851Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.Type: ApplicationFiled: April 1, 2013Publication date: October 2, 2014Inventor: MARK QUANG NGUYEN
-
Publication number: 20140294865Abstract: The invention relates to tumor therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.Type: ApplicationFiled: March 9, 2012Publication date: October 2, 2014Applicant: HEIDELBERG PHARMA GMBHInventors: Werner Simon, Christian Lutz, Christoph Muller, Jan Anderl
-
Publication number: 20140296139Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.Type: ApplicationFiled: March 14, 2014Publication date: October 2, 2014Inventors: Pinchas COHEN, Changhan LEE, Laura J. COBB
-
Publication number: 20140271652Abstract: Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Institute of Arthritis Research, LLCInventor: Craig D. Scoville
-
Publication number: 20140243275Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteosome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.Type: ApplicationFiled: March 29, 2012Publication date: August 28, 2014Applicant: Texas Tech University SystemInventors: Maurizio Chiriva-Internatí, Everardo Cobos, Constance John
-
Publication number: 20140243276Abstract: A method of using a Smac mimetic and pharmaceutical compositions thereof.Type: ApplicationFiled: September 27, 2012Publication date: August 28, 2014Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: David Weng, Srinivas Chunduru, Martin Graham
-
Publication number: 20140227188Abstract: Provided herein are compositions and kits comprising a therapeutic agent linked to a cleavable substrate, wherein the cleavable substrate is capable of being cleaved by cathepsin E. Also provided are methods of treating one or more symptoms of a disease or disorder characterized by expression of cathepsin E in a subject and methods of eliminating a cancer cell characterized by expression of cathepsin E using the provided compositions and kits. Further provided herein are methods of detecting the presence of a cancer cell or detecting a cathepsin E expressing cell using a photosensitizer linked to a cleavable substrate, wherein the cleavable substrate is capable of being cleaved by cathepsin E.Type: ApplicationFiled: February 12, 2014Publication date: August 14, 2014Applicants: Board of Regents, The University of Texas System, The Methodist Hospital SystemInventors: Chin-Hsuan Tung, Wael Refat Adb-Elgaliel, Craig D. Logsdon, Zobeida Cruz-Monserrate
-
Publication number: 20140228290Abstract: The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria (“an XTPP agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.Type: ApplicationFiled: August 2, 2012Publication date: August 14, 2014Applicants: REGENTS OF THE UNIVERSITY OF MICHIGAN, UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Douglas R. Spitz, Michael K. Schultz, Kyle Kloepping, Yueming Zhu, Nukhet Aykin-Burns, Max S. Wicha
-
Publication number: 20140220025Abstract: The present invention is directed toward pharmaceutical compositions comprising an isolated polypeptide and a pharmaceutically acceptable carrier. The present invention also discloses an antibody or an antigen-binding portion thereof that bind to the isolated polypeptide. Methods of inhibiting cancer cells growth are also disclosed, comprising administering the isolated polypeptide or the antibody described herein to a subject in need thereof.Type: ApplicationFiled: February 4, 2014Publication date: August 7, 2014Applicant: Chang Gung Memorial Hospital, Linkou BranchInventors: Tzu-Hao Wang, Chia-Lung Tsai, Angel Chao
-
Patent number: 8796220Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: GrantFiled: June 27, 2012Date of Patent: August 5, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: George Peoples, Sathibalan Ponniah
-
Publication number: 20140212438Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.Type: ApplicationFiled: April 3, 2014Publication date: July 31, 2014Applicant: Yeda Research and Development Co., Ltd.Inventors: Rony SEGER, Dana Chuderland
-
Publication number: 20140212475Abstract: Compositions and pharmaceutical compositions including one or more selenium-containing COX-2 inhibitors are provided according to aspects of the present invention. Methods of treating a subject having or suspected of having cancer are provided according to aspects of the present invention which include administering a therapeutically effective amount of a pharmaceutical composition including a selenium-containing COX-2 inhibitor.Type: ApplicationFiled: January 31, 2014Publication date: July 31, 2014Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: Gavin P. Robertson, Chandagalu D. Raghavendra Gowda, Dhimant H. Desai, Shantu G. Amin
-
Patent number: 8791076Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.Type: GrantFiled: August 31, 2011Date of Patent: July 29, 2014Inventors: Pablo Villoslada, Angel Messeguer
-
Patent number: 8791075Abstract: The invention is directed to a compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove. The present invention is further directed to methods for blocking corepressor binding to a BCL6 lateral groove, methods for inhibiting BCL6 repression in a mammalian cell, and methods for treating a mammal with cancer, wherein the cancer requires BCL6 repression. The present invention is further directed to polypeptides comprising a portion of the corepressor binding site for BCL6 and related polynucleotides and vectors.Type: GrantFiled: June 10, 2009Date of Patent: July 29, 2014Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Ari Melnick, Leandro Cerchietti
-
Publication number: 20140206622Abstract: It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.Type: ApplicationFiled: August 30, 2012Publication date: July 24, 2014Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
-
Publication number: 20140206621Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: ApplicationFiled: November 8, 2013Publication date: July 24, 2014Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Patent number: 8784811Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: GrantFiled: February 22, 2013Date of Patent: July 22, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
-
Publication number: 20140199332Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.Type: ApplicationFiled: December 31, 2013Publication date: July 17, 2014Applicant: International Institute of Cancer Immunology, Inc.Inventor: Haruo SUGIYAMA
-
Patent number: 8778350Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and others.Type: GrantFiled: March 2, 2012Date of Patent: July 15, 2014Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Publication number: 20140194368Abstract: The invention is directed to methods of treating cancer by administration of heat shock protein 70 (Hsp70) to the subject suffering from cancer.Type: ApplicationFiled: January 4, 2013Publication date: July 10, 2014Applicant: Beech Tree Labs, Inc.Inventor: John McMichael
-
Publication number: 20140193398Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.Type: ApplicationFiled: June 28, 2013Publication date: July 10, 2014Inventors: Satoshi Inoue, Hui Ding, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Publication number: 20140193333Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases.Type: ApplicationFiled: June 28, 2012Publication date: July 10, 2014Applicant: OXFORD BIOTHERAPEUTICS LTDInventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20140187496Abstract: The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system and diseases including a feverless response to infection, a cancer or vision loss. Methods of diagnosis of such disease and development anomalies are based on detection of mutations of the SGEF gene or altered levels of the SGEF mRNA or protein. A change of at least about 20% in the level of expression visa-vie a normal individual indicates an SGEF anomaly. The SGEF protein is also used as a preventive or curative treatment of atherosclerosis by local or systemic delivery. The invention also provides a composition comprising an inhibitor of the SGEF gene expression or SGEF protein concentration, as a therapeutic means for glaucoma, osteoarthritis, auto-inflammatory diseases, tumors or cancers.Type: ApplicationFiled: May 17, 2012Publication date: July 3, 2014Inventor: Pierre BITOUN
-
Publication number: 20140186364Abstract: The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.Type: ApplicationFiled: December 19, 2013Publication date: July 3, 2014Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE CLAUDE BERNARD LYON 1, ECOLE NORMALE SUPERIEURE DE LYON, CENTRE LEON BERARDInventors: Patrick Etienne-Roger MEHLEN, Servane Marie-Séverine Tauszig-Delamasure, Céline Jacqueline-Andrée Delloye, Jimena Bouzas-Rodriguez
-
Publication number: 20140186380Abstract: Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.Type: ApplicationFiled: December 4, 2013Publication date: July 3, 2014Applicant: OncoMed Pharmaceuticals Inc.Inventors: Austin L. GURNEY, Fumiko Takada Axelrod
-
Patent number: 8765913Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.Type: GrantFiled: November 2, 2012Date of Patent: July 1, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
-
Publication number: 20140179608Abstract: Described herein are methods to bind a compound to the SH2 domain of Src in a Src-expressing cell which includes contacting a compound comprising an amino acid compound to a Src-expressing cell; and binding a compound to the SH2 domain of Src.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Zi-Jian Xie, Qiqi Ye, Zhichuan Li
-
Patent number: 8754045Abstract: Compositions and methods are provided to destroy internal cancerous lesions selectively by the administration of a combination of a debridement protease enzyme and a denaturant of cell structural proteins and or cell adhesion proteins.Type: GrantFiled: May 14, 2007Date of Patent: June 17, 2014Inventor: James A. Livingston
-
Patent number: 8754035Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.Type: GrantFiled: February 16, 2010Date of Patent: June 17, 2014Assignee: Oncolix, Inc.Inventor: Wen Y. Chen
-
Publication number: 20140162960Abstract: Aspects of the invention include compositions and methods for inhibiting the interaction between scaffold proteins and kinases. These compositions and methods find a number of uses including, for example, suppressing tumor growth and metastasis and reducing tumor size and number in a mammal with cancer.Type: ApplicationFiled: April 5, 2012Publication date: June 12, 2014Applicant: The Board of Trustees of the Leland Stanford Junior universityInventors: Katherine LaRoque Jameson, Paul A. Khavari
-
Publication number: 20140162952Abstract: Provided is a novel cancer-treating agent which can be used as a novel choice for the treatment of cancer. Specifically provided are: a peptide that inhibits binding of ERAP1 polypeptide to PHB2 polypeptide, which comprises a binding site of the ERAP1 polypeptide to the PHB2 polypeptide, and a pharmaceutical composition comprising the peptide. In addition, provided is a method for screening a drug candidate for treating and/or preventing cancer using inhibition of the binding of the ERAP1 polypeptide to PP1? polypeptide, PKA polypeptide or PKB polypeptide as an index.Type: ApplicationFiled: July 27, 2012Publication date: June 12, 2014Applicants: ONCOTHERAPY SCIENCE, INC., THE UNIVERSITY OF TOKUSHIMAInventors: Toyomasa Katagiri, Takuya Tsunoda
-
Patent number: 8748388Abstract: Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof useful as antitumour agents.Type: GrantFiled: December 10, 2008Date of Patent: June 10, 2014Assignee: Pharma Mar, S.A.Inventors: Judit Tulla-Puche, Eleonora Marcucci, Núria Bayó-Puxan, Fernando Albericio, Maria del Carmen Cuevas Marchante